Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An announcement from Lexicon Pharmaceuticals (LXRX) is now available.
Michael Exton, Ph.D., with a robust background in pharmaceutical leadership roles, has been appointed as the CEO and board member of a company, effective July 8, 2024. His experience at Novartis and other firms, along with his dual Ph.D.s, positions him as a qualified leader. Dr. Exton’s compensation includes a $636,000 base salary, up to 70% bonus, and stock options, with incentives aligned with corporate goals. Additionally, Jeffrey L. Wade has been promoted to president and COO, receiving a salary bump and stock options, further strengthening the company’s executive team.
For a thorough assessment of LXRX stock, go to TipRanks’ Stock Analysis page.
